

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 79384

Title: Circulating tumour DNA in gastrointestinal cancer in clinical practice: just a dream or maybe not?

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06325500

Position: Peer Reviewer

Academic degree: PhD

Professional title: Academic Research

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2022-08-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-08-24 01:22

Reviewer performed review: 2022-08-26 02:05

Review time: 2 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The letter to the Editor entitled “Circulating tumour DNA in gastrointestinal cancer in clinical practice: just a dream or maybe not?” describes some considerations of the potential role of circulating tumor DNA (ctDNA) in the management of gastric, biliary, liver, pancreatic and colorectal cancer. In my opinion, this manuscript can be published in current form.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 79384

Title: Circulating tumour DNA in gastrointestinal cancer in clinical practice: just a dream or maybe not?

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05465381

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2022-08-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-08-24 06:13

Reviewer performed review: 2022-08-30 18:49

Review time: 6 Days and 12 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

**Peer-reviewer
statements**Peer-Review: [☐] Anonymous [☒] OnymousConflicts-of-Interest: [☒] Yes [☐] No**SPECIFIC COMMENTS TO AUTHORS**

Minor revisions: - revise the references: in the text, you cite 12 references but only give 11 in the reference list. Comment: ctDNA has not only shown to be more sensitive than CA 19-9, but also to be more sensitive than current gold standard radiological methods (computed tomography) in the display of actual tumor burden at staging (micro dissemination or advanced lymph node status) and restaging (relapse detection); see for example doi: 10.1016/j.ejso.2021.11.138 (12/21) and doi: 10.3389/fonc.2022.902177 (08/22)